Home >

Clinical Trials

In order to win regulatory approval, new drugs must pass through the three phases of clinical trials. To continually improve this years-long and arduous process that involves complex regulations, companies can leverage digital platforms and technologies and new strategies for trial design to make it to the finish line.

Articles

Vaccines of the future

There is a new era of vaccinology in pharma's pipelines

10 tips for improved drug development

Comprehensive strategies to save time and reduce cost in end-to-end clinical development

HIV: An ending in the balance

Incorporating cures into pharma's HIV epidemic equation

Juggling the regulatory complexities of global clinical trials

Deploying an automated process can help simplify safety and compliance information

Taking mental health above ground

It’s imperative that pharma stays on board with solutions

News

AZ, Sanofi closing in on first approval for RSV in 23 years

Bridge Bio, Brainomix partner to use AI in lung fibrosis trial

FDA lifts hold on Sarepta Duchenne trial

Checkpoint to wind down and close cancer trial due to Russia-Ukraine war

FDA lifts Celyad clinical hold

Data in hand, Roche readies to file subcutaneous Tecentriq

Minding the gap

As holes in mental health treatment deepen, can pharma fill the voids?

Global Dose: Focus on Lithuania

A small country looking to make big moves in pharma

Leave no CMC stone unturned

Building a CMC strategy for biologics is a critical, multistep process

2021 Pharma Innovation Awards

Unveiling this year's winners

Mastering the sample management ecosystem

A holistic, flexible approach to managing critical research assets can be a drug development game-changer

The fittest model

Is it time for pharma to evolve its drug development ways?

The next phase of drug creation

Why animal models are on the brink of extinction

Pipeline snapshot: Two treatments that could change the game for Alzheimer’s

It’s no secret that the pipeline for Alzheimer’s treatments has mostly become a sinkhole for dozens of failed drugs and billions in lost R&D dollars. But with the stakes so high...

The Alzheimer's approval maze

Navigating one of the FDA's biggest decisions of the decade

Top pharma industry predictions for 2021

In many ways, the beginning of 2021 isn’t just one of the most welcome New Years of the modern era — it could also be a turning point between the pre-COVID and post-COVID worlds...